

Easy Script – Decision Support Screen

For some medications a **Decision Support** screen may appear. These indicate **major** allergies and drug interactions. If this occurs, you may select an override reason from the drop down list, or click on Free Text and enter a reason in the text box that opens, then click **OK** in the lower right corner of the screen.

If several allergies or interactions appear in the window, each must be addressed separately. **Apply To All** should be used only if appropriate.

Decision Support

IDENTIFIED ORDER:
fentanyl (fentanyl 0.05 mg/mL injectable solution)

ZZSHAKESPEARE, WILLIAM PAVILION
UC803800

Show: Allergy

Status	DC	Type	Severity	Overrid...	Name
		A	●	✔	fentanyl

Previous Override Reason: Free Text

Current Override Reason: Provider aware, DAW Apply To All

Substance: fentanyl

Reaction Class: Allergy **Source:** Patient

Severity:

Reactions: Rash

Comment:

Remove identified order

Drug Reference | Education Leaflet | Reference

fentanyl (fentanyl 0.05 mg/mL injectable solution) Search

fentanyl (fentanyl 0.05 mg/mL injectable solution)

[Pharmacology](#), [Warnings](#), [Pregnancy](#), [Lactation](#), [Side Effects](#), [IV Compatibility](#), [Dosage](#), [Additional Dosage](#)

Pharmacology (Top)

Pharmacology

Fentanyl is a potent synthetic opiate agonist which has a mechanism of action similar to that of morphine.

Fentanyl, like other opiate agonists, exerts effects at a variety of sites within the central nervous system. It is believed to act as an agonist with several opiate receptors including the mu-, kappa- and delta-receptors. These receptors mediate, in part, some of the important pharmacologic effects of opiate agonists including analgesia, respiratory depression, sedation, miosis, nausea, and decreased gastrointestinal motility.

Fentanyl is approved by the FDA for use as a preoperative, and preprocedure, sedative and as an adjunct to the induction and maintenance of general and regional anesthesia. Fentanyl iontophoretic transdermal system is approved for the short-term management of acute postoperative pain in patients requiring opioid analgesia during hospitalization. Oral transmucosal fentanyl citrate is approved only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

OK